

parameters									
Duration of incontinence (mo.)**	18 (9–24)	23 (7–36)	23 (7–28)	0.79		12 (7–24)	24 (7–24)	24 (12–28)	0.099**
Pad weight (mg/daily)	650 (200–1000)	850 (600–1000)	900 (300–1000)	0.49		700 (200–1000)	1000 (600–1000)	900 (500–1000)	0.387
Symptom score	18.5 (16–21)	21 (19–21)	19 (16–21)	0.14		20 (16–21)	21 (16–21)	19 (16–21)	0.524
VLPP (cmH2O)	10 (5–15)	7.5 (5–15)	7.5 (5–20)	0.831		10 (5–15)	10 (5–15)	5 (5–20)	0.646

Table 2. Distributions of clinical parameters




Figure 1. Severe periurethral fibrosis on pelvic MRI in study group patient after RRP on the left image. No periurethral fibrosis on pelvic MRI in control group patient after RRP on the right image.

Specify source of funding or grant	We have no financial or commercial interests for our manuscript. Also, it should be declared that the results of this clinical study had been published in Urology journal (Urology. 2006 Dec, 68(6):1308-12). But, we will firstly present this abstract in an international meeting, if acceptance is confirmed.
Is this a clinical trial?	Yes
Is this study registered in a public clinical trials registry?	No
What were the subjects in the study?	HUMAN
Was this study approved by an ethics committee?	Yes
Specify Name of Ethics Committee	Diskapi Yildirim Beyazit Training and Research Hospital
Was the Declaration of Helsinki followed?	Yes
Was informed consent obtained from the patients?	Yes